A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.

Abstract

To date, four rituximab biosimilars have received regulatory approval from the European Medicines Agency and/or US Food and Drug Administration. CT-P10 was the first rituximab biosimilar to be approved by each agency, in 2017 and 2018, respectively. Regulatory approval of CT-P10 followed demonstration of pharmacokinetic equivalence to the reference product in a phase I study in patients with rheumatoid arthritis. Phase III pivotal studies of CT-P10 subsequently demonstrated equivalence or non-inferiority of pharmacokinetics and efficacy between CT-P10 and reference rituximab in patients with rheumatoid arthritis, advanced-stage follicular lymphoma, and low-tumour-burden follicular lymphoma. Almost 5 years after its initial regulatory approval, significant real-world experience has accumulated with CT-P10 use, particularly in diffuse large B-cell lymphoma, one of the indications approved by extrapolation. This article summarises the pivotal data underlying regulatory approval for the four licensed rituximab biosimilars, before focusing on real-world data gathered with CT-P10. These data provide further support for the safety and effectiveness of CT-P10 and should boost healthcare professional and patient confidence in its use. Pharmacoeconomic analyses support the potential healthcare system cost savings offered by rituximab biosimilar uptake, which could lead to improved patient access to biologic treatments. Opportunities arising from biosimilar uptake extend further, potentially enabling innovative investigator-led research and therapeutic advances.

• Authors: Dasom Choi, Soohyun Lee, Seungmin Kim, Sangwook Yoon
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 42 Issue 4 Pg. 285-300 (Apr 2022) ISSN: 1179-1918 [Electronic] New Zealand
• PMID: 35325438 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Biosimilar Pharmaceuticals
• CT-P10
• Rituximab

Topics

• Antibodies, Monoclonal, Murine-Derived
• Arthritis, Rheumatoid (drug therapy)
• Biosimilar Pharmaceuticals (adverse effects, pharmacokinetics)
• Clinical Trials, Phase I as Topic
• Humans
• Lymphoma, Follicular (drug therapy, pathology)
• Rituximab (pharmacokinetics, therapeutic use)